BioToxTech Co

BioToxTech Co EPS

The Earnings per Share (EPS) of BioToxTech Co (086040.KQ) as of Nov 19, 2026 is 80.00 KRW. In the previous year, Earnings per Share (EPS) was -442.22 KRW — a change of -118.09% (higher).

EPS

80.00KRW

YoY

-118.09%

Last updated:

Earnings per Share (EPS) of BioToxTech Co is 2025 80.00 KRW. Earnings per Share (EPS) of BioToxTech Co was 2024 -442.22 KRW. It decreases by -118.09% higher compared to the previous year.

The BioToxTech Co EPS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EPS
Date
EPS
Jan 1, 2018
249.36 KRW
Jan 1, 2019
-108.84 KRW
Jan 1, 2020
179.83 KRW
Jan 1, 2021
489.48 KRW
Jan 1, 2022
187.51 KRW
Jan 1, 2023
-335.60 KRW
Jan 1, 2024
-442.22 KRW
Jan 1, 2025
80.00 KRW
The BioToxTech Co EPS history
YEAREPSYoY
80.00KRW-118.09%
-442.22KRW+31.77%
-335.60KRW-278.98%
187.51KRW-61.69%
489.48KRW+172.19%
179.83KRW-265.23%
-108.84KRW-143.65%
249.36KRW+159.34%
96.15KRW+33.76%
71.88KRW-126.75%
-268.69KRW-13.75%
-311.53KRW-435.08%
92.97KRW-58.73%
225.26KRW+536.31%
35.40KRW-92.31%
460.11KRW-145.33%
-1,015.00KRW-4,221.83%
24.63KRW-70.33%
83.00KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioToxTech Co Stock analysis

What does BioToxTech Co do? Biotoxtech Co., Ltd. generates revenue through non-clinical drug trials, offering safety evaluation research, efficacy evaluation research, and analysis research services. Safety evaluation includes general toxicity, local toxicity, reproductive and development, genotoxicity, immunotoxicity, carcinogenicity, safety pharmacology, ecotoxicology, histopathology, and hematology tests. Efficacy evaluation covers medical supplies, health supplements, and cosmetics. Analysis research provides pharmacokinetics (PK) and toxicokinetics (TK) tests, validation, and bio analysis services. The company serves clients requiring preclinical testing for pharmaceuticals, health products, and cosmetics. The firm expanded its operations by acquiring a 60% stake in a newly established subsidiary on March 13, 2013. This strategic move enhances its capacity to deliver comprehensive research services. Clients include pharmaceutical companies, health supplement manufacturers, and cosmetic brands seeking regulatory compliance and product safety validation before market entry. Biotoxtech's service portfolio targets the pharmaceutical, health supplement, and cosmetic industries. Its safety and efficacy testing ensures products meet regulatory standards, supporting clients in developing safe and effective formulations. The company's analysis research further aids in optimizing drug delivery and performance through PK and TK assessments. BioToxTech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioToxTech Co stock

Earnings per Share (EPS) of BioToxTech Co is 80.00 KRW in 2025.

Earnings per Share (EPS) of BioToxTech Co changed from -442.22 KRW to 80.00 KRW, representing a -118.09% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Earnings per Share (EPS) BioToxTech Co since 2006 – with annual values, charts, and detailed analysis.

Earnings per Share measures the portion of a company's profit allocated to each outstanding share. It is a key metric for assessing a company's profitability on a per-share basis.

EPS = Net Income / Shares Outstanding

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — BioToxTech Co

All Key Metrics — BioToxTech Co